Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2
Dr Antonio Passaro reports on key results from ESMO Congress 2023 on LBA15 - Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated Advanced NSCLC After Progression on Osimertinib: MARIPOSA-2, a Phase 3, Global, Randomized, Controlled Trial
Produced by the European Society for Medical Oncology
http://oncologypro.esmo.org
![Frightened Rabbit - Backyard Skulls [Official Video]](https://images.mixrolikus.cc/video/bx7dF89a3z4)
